Xiaodong Li1,2,3, Wenwei Hu1,2,3, Xiao Zheng2,3, Chu Zhang1, Peng Du2,3, Zhuojun Zheng4, Yan Yang1, Jun Wu1, Mei Ji1, Jingting Jiang2,3, Changping Wu1,2,3. 1. a Department of Oncology , The Third Affiliated Hospital of Soochow University , Changzhou , China. 2. b Department of Tumor Biological Treatment , The Third Affiliated Hospital of Soochow University , Changzhou , China. 3. c Jiangsu Engineering Research Center for Tumor Immunotherapy , Changzhou , China. 4. d Department of Hematology , The Third Affiliated Hospital of Soochow University , Changzhou , China.
Abstract
BACKGROUND: Immunotherapy with immune checkpoint inhibitors has emerged as promising treatment modality for cancer based on the success of anti-CTLA-4 and -PD-1/PD-L1 antibodies. LAG-3 and TIM-3 are two new immune checkpoints. The aim of this work is to review the role and application of LAG-3 and TIM-3 for cancer immunotherapy. MATERIAL AND METHODS: Literatures were searched and collected in Medline/PubMed. RESULTS: LAG-3 is presented as a CD4 homolog type I transmembrane protein which binds MHC class II molecules. LAG-3 negatively regulates T cell proliferation, homeostasis and function. IMP321 is formed of an extracellular portion of human LAG-3 fused to the Fc fraction of human IgG1 and has shown increased T cell responses and tolerability in phase I studies on advanced renal cell cancer. When combined with paclitaxel, IMP321 has exerted immune enhancement and tumor inhibition with no significant IMP321-related adverse events. TIM-3 belongs to the TIM family and mainly negatively regulates Th1 immunity. The TIM-3/galectin-9 pathway contributes to the suppressive tumor microenvironment. TIM-3 overexpression is associated with poor prognosis in a variety of cancers. Both LAG-3 and TIM-3 are coexpressed with other immune checkpoints. The application of LAG-3 or TIM-3 does play an important role in anti-tumor responses, and maybe better when combing with anti-CTLA-4 and anti-PD-1/L1 antibodies. CONCLUSIONS: These two immune checkpoints play crucial roles in cancer development and may be used in future clinical practice of cancer therapy.
BACKGROUND: Immunotherapy with immune checkpoint inhibitors has emerged as promising treatment modality for cancer based on the success of anti-CTLA-4 and -PD-1/PD-L1 antibodies. LAG-3 and TIM-3 are two new immune checkpoints. The aim of this work is to review the role and application of LAG-3 and TIM-3 for cancer immunotherapy. MATERIAL AND METHODS: Literatures were searched and collected in Medline/PubMed. RESULTS:LAG-3 is presented as a CD4 homolog type I transmembrane protein which binds MHC class II molecules. LAG-3 negatively regulates T cell proliferation, homeostasis and function. IMP321 is formed of an extracellular portion of humanLAG-3 fused to the Fc fraction of human IgG1 and has shown increased T cell responses and tolerability in phase I studies on advanced renal cell cancer. When combined with paclitaxel, IMP321 has exerted immune enhancement and tumor inhibition with no significant IMP321-related adverse events. TIM-3 belongs to the TIM family and mainly negatively regulates Th1 immunity. The TIM-3/galectin-9 pathway contributes to the suppressive tumor microenvironment. TIM-3 overexpression is associated with poor prognosis in a variety of cancers. Both LAG-3 and TIM-3 are coexpressed with other immune checkpoints. The application of LAG-3 or TIM-3 does play an important role in anti-tumor responses, and maybe better when combing with anti-CTLA-4 and anti-PD-1/L1 antibodies. CONCLUSIONS: These two immune checkpoints play crucial roles in cancer development and may be used in future clinical practice of cancer therapy.
Authors: Shelby Lennon; Ayman Oweida; Dallin Milner; Andy V Phan; Shilpa Bhatia; Benjamin Van Court; Laurel Darragh; Adam C Mueller; David Raben; Jorge L Martínez-Torrecuadrada; Todd M Pitts; Hilary Somerset; Kimberly R Jordan; Kirk C Hansen; Jason Williams; Wells A Messersmith; Richard D Schulick; Philip Owens; Karyn A Goodman; Sana D Karam Journal: Clin Cancer Res Date: 2019-04-03 Impact factor: 12.531
Authors: Ayman J Oweida; Adam C Mueller; Miles Piper; Dallin Milner; Benjamin Van Court; Shilpa Bhatia; Andy Phan; Thomas Bickett; Kimberly Jordan; Theresa Proia; Richard Schulick; Wells A Messersmith; Marco Del Chiaro; Eric Clambey; Michael J Gough; Jason Williams; Kirk Hansen; Karyn Goodman; Sana D Karam Journal: Cancer Immunol Immunother Date: 2020-10-23 Impact factor: 6.968
Authors: Ornella Franzese; Francesco Torino; Maria Pia Fuggetta; Angelo Aquino; Mario Roselli; Enzo Bonmassar; Anna Giuliani; Stefania D'Atri Journal: Oncotarget Date: 2017-06-20